8-KOther Events

CVS HEALTH Corp 8-K Report, Corporate Update (Mar 8, 2018)

Filed March 8, 2018For Securities:CVS

Summary

This Form 8-K filing by CVS Health Corporation (CVS) on March 8, 2018, primarily addresses a supplemental disclosure related to the previously announced merger with Aetna Inc. A shareholder class action lawsuit was filed by a CVS Health stockholder challenging the merger and alleging breaches of fiduciary duty by the CVS Health Board and insufficient disclosure in the preliminary proxy statement. CVS Health, while believing the claims are without merit, has voluntarily supplemented its disclosures to avoid potential delays or adverse effects on the transaction. This supplemental information aims to address the plaintiff's concerns, leading to the plaintiff's agreement to dismiss the lawsuit. The company emphasizes that this disclosure does not constitute an admission of liability or wrongdoing.

Key Highlights

  • 1CVS Health is filing supplemental disclosures to its joint proxy statement/prospectus regarding the Aetna merger.
  • 2A shareholder class action lawsuit ('Gawrych v. Merlo et al.') was filed against CVS Health directors and the company.
  • 3The lawsuit alleges breaches of fiduciary duty and inadequate disclosure concerning the Aetna merger.
  • 4CVS Health believes the lawsuit's claims are without merit but is providing supplemental disclosures to mitigate transaction risks.
  • 5Supplemental disclosures clarify the rationale for selecting Aetna over other potential transactions and provide details on the selection of financial advisors (Barclays and Goldman Sachs).
  • 6Information regarding the net long position of Barclays in Aetna shares and Goldman Sachs' lack of direct equity investment in Aetna as of the opinion date is also disclosed.
  • 7The plaintiff has agreed to dismiss the lawsuit in light of the supplemental disclosures, with CVS Health denying any legal necessity for these additional disclosures.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide supplemental disclosures to the joint proxy statement/prospectus related to CVS Health's proposed merger with Aetna. These disclosures are made in response to a shareholder class action lawsuit.

The shareholder lawsuit alleged that the CVS Health Board breached their fiduciary duties in negotiating the merger agreement and that CVS Health failed to disclose material information in its preliminary proxy statement/prospectus regarding the Aetna merger.

CVS Health is providing supplemental disclosures voluntarily to avoid the risk of adverse effects or delays on the Aetna merger transaction and to minimize the costs, risks, and uncertainties associated with litigation. They explicitly state this is not an admission of liability.

The supplemental disclosures clarify that the CVS Health board determined a transaction with Aetna offered a more favorable value creation opportunity than potential transactions with two other managed care companies. Additionally, they provide details on the selection of Barclays and Goldman Sachs as financing sources, citing their reputations, experience, and familiarity with the transaction. Further details include the extent of Barclays' net long position in Aetna shares and Goldman Sachs' equity investments in Aetna as of the date of their opinion.